Former Deputy Director Of China's Drug Regulatory Agency Could Face Trial On Corruption Charges
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Eight months after coming under scrutiny of the Chinese Communist Party's top anti-corruption commission, a deputy director of China's State FDA has been expelled from the Party and could face trial, according to central government officials
You may also be interested in...
China's Simcere Looks To Move Past Vaccine Troubles, Focuses On New GMP Requirements, Partnering With Big Pharma
BEIJING - Leading Chinese drug maker Simcere Pharmaceutical Group, which develops innovative medicines, first-to-market generics and biosimilars, reported this week that its earnings for 2010 skyrocketed, despite its takeover of a vaccine producer that was slapped with substantial fines last year for turning out a "substandard rabies vaccine.
China's Simcere Looks To Move Past Vaccine Troubles, Focuses On New GMP Requirements, Partnering With Big Pharma
BEIJING - Leading Chinese drug maker Simcere Pharmaceutical Group, which develops innovative medicines, first-to-market generics and biosimilars, reported this week that its earnings for 2010 skyrocketed, despite its takeover of a vaccine producer that was slapped with substantial fines last year for turning out a "substandard rabies vaccine.
China's State FDA Steps Up Transparency With First Annual Review Of Drug Approval Process, Outcome
BEIJING - In a step toward lifting a longstanding veil on the drug review process in China, the State FDA has for the first time issued a public outline of the range and types of medicines approved by regulators last year